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Abstract
Background
Favorable treatment outcomes with TNF blockade led us to explore cytokine responses in
hidradenitis suppurativa (HS).
Methods
Blood monocytes of 120 patients and 24 healthy volunteers were subtyped by flow cytome-
try. Isolated blood mononuclear cells (PBMCs) were stimulated for cytokine production; this
was repeated in 13 severe patients during treatment with etanercept. Cytokines in pus were
measured.
Results
CD14brightCD16dim inflammatory monocytes and patrolling monocytes were increased in
Hurley III patients. Cytokine production by stimulated PBMCs was low compared to controls
but the cytokine gene copies did not differ, indicating post-translational inhibition. The low
production of IL-17 was restored, when cells were incubated with adalimumab. In pus, high
concentrations of pro-inflammatory cytokines were detected. Based on the patterns, six dif-
ferent cytokine profiles were discerned, which are potentially relevant for the choice of treat-
ment. Clinical improvement with etanercept was predicted by increased production of IL-1β
and IL-17 by PBMCs at week 8.
Conclusions
Findings indicate compartmentalized cytokine expression in HS; high in pus but suppressed
in PBMCs. This is modulated through blockade of TNF.
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Introduction
Hidradenitis suppurativa (HS) is a chronic devastating skin disorder affecting areas rich in apo-
crine glands. Nodules appear in the affected areas; they progressively become swollen and rup-
ture with the release of pus. This process occurs repeatedly, ending to sinus tract formation and
scars [1]. HS seems to indiscriminately affect the global population. Although the exact epide-
miology is unknown, a recent large epidemiological survey in France reports 0.97% disease
prevalence [2]. HS has considerable impact on the quality of life of patients, often leading to
loss of many working hours per month. The Dermatology Quality Life Index (DQLI) for HS is
8.9, being thus higher than any other skin disorder [3].
We have previously demonstrated defective lipopolysaccharide (LPS)-induced production of
the pro-inflammatory cytokines TNFα and IL-6 by blood monocytes of patients with HS [4].
This finding is a paradox since HS skin lesions are heavily inflamed and often they respond to
anti-cytokine treatment either with agents blocking TNFα [5] or with agents blocking IL-1β and
IL-1α [6]. Puzzled by this paradox, the current study was undertaken to better understand the
role and the regulation of the various pro-inflammatory cytokines in HS. We wanted to know
which monocyte populations and subpopulations (i.e. inflammatory monocytes and patrolling
monocytes) are involved. Also we wanted to understand whether peripheral cytokine production
is inhibited at the transcriptional or post-transcriptional level and whether this phenomenon of
down-regulation is modulated by anti-TNF treatment. Finally, we aimed to find out the cytokine
profile at the level of the inflammatory lesions, by measuring cytokines is pus.
Methods
Study population
The study was conducted during the period September 2009 to January 2012 in patients under
follow-up in the Outpatient Department of Immunology and Infectious Diseases of the ATTI-
KONUniversity Hospital (approval 103/24.03.2009). The study was approved by the Ethics
Committee of the hospital. Written informed consent was provided by all patients and controls.
Diagnosis of HS was based on the following criteria: a) onset early after puberty; b) presence
of subcutaneous nodules in areas of skin rich in apocrine glands; and c) a compatible history of
recurrent drainage of pus from the affected areas [3, 7].
Clinical characteristics of patients were recorded comprising demographics, age since dis-
ease onset, involved areas and Hurley stage of severity. Lesions were graded according to the
clinical system of Hurley [3, 7]. The severity of the disease was assessed during follow up of
these patients according to the scoring system proposed by Sartorius et al [8]. Whole blood was
collected from patients after venipuncture of one forearm vein under aseptic conditions. Blood
sampling was repeated for some patients under treatment with anti-TNF agents. Blood sam-
pling was also performed from 24 healthy volunteers. When available, pus was collected from
the HS lesions, as indicated below.
Flow cytometry
In order to study the monocyte subsets, four ml of whole blood were collected into ethylenedia-
mine tetraacetic acid (EDTA)-coated tubes. Whole blood was incubated for 15 minutes in the
dark with the flurochrome-conjugated monoclonal antibodies anti-CD14 (FITC, emission 525
nm, Immunotech, Marseille, France); anti-CD16 (PE, emission 525 nm, Immunotech); and anti-
CD45 (PC5, emission 680 nm, Immunotech). Red blood cells were lysed (VersaLyse Solution,
Immunotech, Marseille, France) and white blood cells were fixed with 0.16% formaldehyde (Fix-
ative Solution, Immunotech). For each sample isotypic IgG controls were used. Cells were
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analyzed after running through the CYTOMICS FC flow cytometer (Beckman Coulter Co,
Miami, Florida) with gating for monocytes based on their characteristic side scattering and CD45
expression. Absolute counts were determined using fluorospheres (Flow count, Immunotech).
Cytokine production assays
Isolation of peripheral blood mononuclear cells (PBMCs) and stimulation for cytokine produc-
tion were done as described elsewhere [9]. Cytokine stimuli were: 10 ng/ml of LPS of Escheri-
chia coli O55:B5; 1x106 colony forming units (cfu)/ml of heat-killed Candida albicans
(HKCA); and 1x106 cfu/ml of heat-killed Staphylococcus aureus (HKSA). HKCA and HKSA
were prepared after heating 5x108 cfu/ml of live isolates derived from pus cultures of lesions of
patients with HS, for four hours at 70°C. Absence of growth was verified, after the end of heat-
ing, by subculture onto Saboureaud’s agar and onto blood agar respectively. The experiments
were performed in the absence/presence of 10μg/ml of adalimumab (Abbott Laboratories, Chi-
cago, IL). This concentration was selected because it is within the range of steady state serum
concentrations after administration of conventional doses [10].
Concentrations of TNFα, IL-1β IL-6, IL-10 and IL-1ra were measured in supernatants of
the 24-hour incubation; those of IL-17, IL-22 and human β-defensin-2 (hBD-2) in superna-
tants of the 5-day incubation. Cytokines were measured in duplicate by ELISA (R&DMinneap-
olis, USA). The lowest detection limits were: 40 pg/ml for TNFα; 20 pg/ml for IL-1β, IL-6,
ΙL-10 and IL-1ra; 78 pg/ml for IL-17 and IL-22; and 6 pg/ml for hBD-2.
Quantitative PCR for mRNA expression of IL-1β and TNFα
To measure cytokine specific mRNA, isolated PBMCs at a density of 2x106/ml were left unsti-
mulated or stimulated with1ng/ml LPS of E. coli O55:B5 for 4 hours at 37°C in 5% CO2 under
the growth conditions described above into wells of 12-well plates. Then plates were centri-
fuged, supernatants were discarded and cells were lysed with Trizol (Invitrogen, Karlsruhe,
Germany) and kept at −80°C until extraction of RNA. RNA extraction, synthesis of cDNA and
measurements of gene transcripts was done as described elsewhere [9].
Pus collection
Pus was collected from lesions of patients naïve to any therapy with TNF antagonists. The area
of lesions was cleaned with sterile gauze moistened with normal saline 0.9% before the collec-
tion of pus. After prudent palpation of a representative draining fistula, a plastic 20G needle
was put inside the fistula and 100 μl of pus were aspirated into an insulin syringe applied at the
end of the needle. Pus was diluted with 900 μl of water for injection (dilution 1:10). The final
volume of 1 ml was poured into a sterile Eppendorf tube and kept at -70°C until cytokine mea-
surement. Concentrations of cytokines were measured as described above.
Treatment with etanercept
Thirteen patients with Hurley III stage disease were given therapy with the TNF antagonist eta-
nercept. None of the patients had been enrolled in the previous published trial of our group
[11]. Ideally, these patients should have received treatment with adalimumab since adalimu-
mab was added in the cultures of PBMCs. However, since results of a previous phase 2 clinical
study of our group approved by the National Organization for Medicines of Greece showed
considerable benefit from the use of etanercept in patients, the National Organization for Med-
icines of Greece approved only the off-label treatment with etanercept for these patients after
application by the treating physician (author EGB). All patients provided written informed
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consent for this off-label treatment. Etanercept was administered subcutaneously at a dose of
50 mg twice weekly for 24 weeks. Before start of treatment all patients were thoroughly investi-
gated so that they were bearing negative skin tuberculin test; negative chest X-ray; negative
serology for human immunodeficiency virus (HIV), for hepatitis B virus (HBV) and for hepati-
tis C virus (HCV); negative case-history and family history for any demyelinating disorder;
and normal liver biochemistry.
Blood sampling for isolation and stimulation of PBMCs and for separation of serum was
done before start of treatment and eight weeks from start of treatment. This time point was
arbitrarily chosen. At the end of treatment patients were divided into responders if they had a
decrease of Sartorius score by more than 30% from the baseline, or non-responders when
patients experienced persistence of pain and purulence from the affected skin areas. Concen-
trations of C-reactive protein (CRP) were measured in serum samples by an immunoturbido-
metric assay (Roche, Paris, France, lower detection limit 3.2 mg/l).
Statistical analysis
Results were expressed as means ± SE. Comparisons of the absolute counts of monocyte sub-
sets between healthy controls and patients at different Hurley stages were done by ANOVA
with post-hoc analysis by Bonferroni. Comparisons of cytokine stimulation between healthy
controls and patients were done by the Mann-Whitney U test. Comparisons of treated PBMCs
in the absence and in the presence of adalimumab were performed using the Wilcoxon’s rank
signed test. Percent changes of cytokine production from the baseline on the eighth week from
start of treatment with TNF antagonists were measured. Comparisons between patients who
did not improve and patients who improved were done by the MannWhitney U test. Statistical
correlations were done according to Spearman’s rank of order. Median concentration of each
cytokine was determined in pus. Based on this measurement patients were divided with high
production (above the median) and low production (below the median) of each specific cyto-
kine. After cross-tabulation and TURF analysis, patients were classified according to the
expressed pattern of cytokines. Any value of p below 0.05 after adjustment for multiple com-
parisons by Bonferroni was considered significant (S1 File).
Results
Study population
A total of 120 patients with HS were enrolled in the study; 39 patients were classified as stage I
disease according to Hurley; 37 patients as stage II disease; and 44 patients as stage III disease.
Their characteristics are shown in Table 1. Mean ± SD age of controls was 37.3 ± 11.1 years
(p: 0.163 compared with patients); nine controls were male and fifteen were female (p: 0.232
compared with patients).
Monocyte subpopulations
The absolute count of subpopulations of circulating monocytes in patients and in healthy volun-
teers is given in Fig 1. There was a tendency of an increase in total numbers of monocytes, as well
as in monocytes with the inflammatory phenotype CD14brightCD16dim and in patrolling mono-
cytes (CD14negativeCD16bright or CD14dimCD16bright) among HS patients. The increases were signif-
icant for the Hurley stage III patients. A positive correlation was found between the absolute count
of monocytes and the Sartorius score (rs: +0.361, p: 0.003). Since inflammatory monocytes are con-
sidered as the main producers of pro-inflammatory cytokines, it was concluded that the low cyto-
kine production by these cells described previously [4] was not due to a depletion of these cells.
Cytokines in Hidradenitis Suppurativa
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Cytokine production
The production of TNFα, IL-1β, IL-6, IL-10, IL-17, IL-22 and IL-1ra by PBMCs of healthy con-
trols and by PBMCs of patients with HS is shown in Fig 2. Production of cytokines by PBMCs
of patients was low compared to controls. This was not only the case for the pro-inflammatory
cytokines but also for the inhibitory cytokines IL-1ra and IL-10. This phenomenon appeared to
be dependent to some extent of the applied stimulus. Production of TNFα was decreased after
stimulation with HKCA (Fig 2A); that of IL-1β and IL-6 after stimulation with LPS (Fig 2B and
2C); that of IL-1ra and of IL-10 with all three studied stimuli (Fig 2D and 2G); and that of IL-
17 after stimulation with HKCA and HKSA (Fig 2E). Production of hBD-2 was below the
lower limit of detection in all samples (data not shown).
As shown in Fig 2H, transcripts of TNF and of IL-1β did not differ between HS patients and
healthy volunteers, pointing out that there is an inhibition at the post-transcriptional level.
For each of the defective cytokine responses to the stimuli mentioned, we assessed whether
they are related to the Hurley disease stage. We compared patients in Hurley stages I/II with the
most severe stage Hurley III. Patients at Hurley III disease stage had impaired production for IL-
17 and to a lesser extent for IL-10 (Fig 3). Significant differences were not found for the other
cytokines between patients with Hurley I/II and patients with Hurley III stage (data not shown).
Thereafter, we investigated whether defective cytokine production is changed when the cells
are co-incubated with the anti-TNF agent adalimumab (Fig 4). The production of IL-17 after
stimulation with either HKCA or HKSA significantly increased in the presence of adalimumab.
Such changes were not seen for any other cytokine.
Cytokine concentrations in pus
The next step was to obtain pus from patients with HS and measure cytokines in these samples.
As can be seen in Fig 5A, sizable concentrations of TNFα, IL-1β and IL-1ra were present in the
pus of all patients and none of the patients had concentrations of any of these cytokines below
the lower detection limit. However, 25.0% of patients had pus IL-1α below the detection limit,
Table 1. Clinical characteristics of patients enrolled in the study.
Number of patients 120
Age (years, mean ± SD) 37.3 ± 5.9
Male/Female (number, %) 43 (35.8)/77(64.2)
Years from initial diagnosis (median, range) 10.0 (1.0–35.0)
Disease stage (number, %)
Hurley I 39 (32.5)
Hurley II 37 (30.8)
Hurley III 44 (36.7)
Sartorius score by Hurley stage (mean ± SD)
Hurley I 28.1 ± 20.2
Hurley II 52.4 ± 24.9
Hurley III 129.3 ± 79.2
Involved body areas (number, %)
Axillae 66 (55.0)
Submammary folds 30 (25.0)
Femoral folds 96 (80.0)
Groins 47 (39.2)
Perianal area 53 (44.2)
doi:10.1371/journal.pone.0130522.t001
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15.4% had pus IL-6 below the detection limit, 71.4% had pus IL-10 below the lower detection
limit and 78.6% had pus IL-17 below the detection limit. Furthermore, positive correlations were
found between the absolute counts of circulating patrolling monocytes and the concentrations of
TNFα (rs: +0.675, p: 0.032) and of IL-1β (rs: +0.778, p: 0.008) in pus (Fig 5B and 5C). The years
since onset of HS correlated positively with IL-6 in pus and not with the other cytokines (Fig 5D).
According to the concentrations of cytokines in pus, patients were classified into six patterns
of cytokine expression taking into consideration if patients had high or low concentrations of
TNFα, high or low concentrations of IL-1β and high or low concentrations of any one of the
other five measured interleukins (Fig 5E). The most common expression patterns were i) low
TNFα, high IL-1β and high ILs found in 25% of patients; ii) high TNFα, high IL-1β and high ILs
found in 21.4% of patients; and iii) low TNFα, low IL-1β and low ILs found in21.4% of patients.
Effect of treatment with etanercept on cytokine production
To investigate the effect of anti-TNF treatment, PBMCs of 13 Hurley stage III patients were
investigated for cytokine production before and during treatment. Production of cytokines
tended to increase after treatment if the patient improved; lack of improvement was associated
with a tendency to decreased production (Fig 6A, 6B and 6C). For the HKSA-induced
Fig 1. Monocyte subsets in HS. Absolute counts of (A) total circulating monocytes, (B) CD14bright/CD16neg monocytes, (C) CD14bright/CD16dim monocytes,
and (D) patrolling monocytes are shown for healthy volunteers (n = 14), patients with Hurley I HS (n = 37), with Hurley II HS (n = 37) and with Hurley III HS
(n = 44). P values of comparisons by ANOVA and post hoc Bonferroni corrections: a0.004 vs healthy controls; b0.026 vs Hurley I; c0.001 vs healthy controls;
d0.012 vs Hurley I; e0.008 vs Hurley II; f0.037 vs healthy controls.
doi:10.1371/journal.pone.0130522.g001
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Fig 2. Stimulation of circulatingmonocytes. Production of (A) tumour necrosis factor-alpha (TNFα), (B) interleukin (IL)-1β, (C) IL-6, (D) IL-10, (E) IL-10, (F)
IL-22, and (G) IL-1ra by peripheral blood mononuclear cells (PBMCs) of eight healthy controls and of 80 patients with hidradenitis suppurativa (HS). PBMCs
Cytokines in Hidradenitis Suppurativa
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were stimulated with LPS of Escherichia coliO55:B5; with heat-killedCandida albicans (HKCA), and with heat-killed Staphylococcus aureus (HKSA). (H)
Gene transcripts of TNF and of IL-1 after stimulation with LPS. P values refer to comparisons with healthy controls by the Mann-Whitney U test; pNS:
difference not-significant.
doi:10.1371/journal.pone.0130522.g002
Fig 3. Stimulation of IL-10 and IL-17 in relation with disease severity Production of IL-10 and IL-17 was
stimulated in peripheral blood mononuclear cells (PBMCs) of patients with hidradenitis suppurativa (HS) by
LPS of Escherichia coliO55:B5, heat-killedCandida albicans (HKCA) and heat-killed Staphylococcus aureus
(HKSA). Patients are divided into those with Hurley I or Hurley II disease stage (n = 50) and into those with
Hurley III disease stage (n = 40). P values refer to comparisons between disease stages by the Mann
Whitney U test; pNS: difference not-significant.
doi:10.1371/journal.pone.0130522.g003
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production of IL-1β and IL-17 these changes were significant. Serum concentrations of CRP
were increased in patients without improvement (Fig 6D).
Fig 4. Modulation of cytokine release by adalimumab. Peripheral blood mononuclear cells (PBMCs) from of eight healthy controls and 40 patients with
hidradenitis suppurativa were stimulated for the production of (A) interleukin (IL)-1β with LPS of Escherichia coliO55:B5; (B) IL-6 with LPS of E.coliO55:B5;
(C) IL-10 with LPS of E.coliO55:B5; (D) IL-10 with heat-killedCandida albicans (HKCA); (E) IL-10 with heat-killed Staphylococcus aureus (HKSA); (F) IL-1ra
with HKSA; (G) IL-17 with HKCA; (H) IL-17 with HKSA. P values refer to comparisons of cytokine production without/with adalimumab; pNS: difference not-
significant.
doi:10.1371/journal.pone.0130522.g004
Fig 5. Cytokine concentrations in pus of patients with HS. (A) Concentrations of tumour necrosis factor-alpha (TNFα), interleukin (IL)-1β, IL-1α, IL-6, IL-
10, IL-17 and Il-1ra were measured in the pus of the lesions of 28 patients of Hurley III disease stage. Lines represent medians. Correlations between (Β) the
number of patrolling monocytes and pus TNFα; (C) the number of patrolling monocytes and pus IL-1β; and (D) IL-6 and years since disease onset.
Classification patterns of patients according to pus cytokines is shown in panel E. Spearman’s coefficients of correlation and p values of significance are
provided.
doi:10.1371/journal.pone.0130522.g005
Cytokines in Hidradenitis Suppurativa
PLOS ONE | DOI:10.1371/journal.pone.0130522 June 19, 2015 10 / 15
Discussion
In the present study, we have found that pus derived from lesions of patients with HS contains
high concentrations of pro-inflammatory cytokines (TNFα, IL-1β, IL-1α, IL-17) and of anti-
inflammatory cytokines (IL-10 and IL-1ra). Surprisingly, the profile of these cytokines differs
considerably between patients. Monocytes from the circulation of HS patients are predomi-
nantly of the inflammatory phenotype, but they are refractory to respond to the conventional
stimuli to produce cytokines. The refractoriness is regulated at the post-transcriptional level,
since there are high specific mRNA concentrations present in these monocytes.
Our finding that different patients exhibit different cytokine profiles in pus is important for
several reasons. First of all, it teaches us that the defect is not residing in the regulation of just
one of these cytokines. This is unlike the situation in most auto-inflammatory disorders, such
as familial Mediterranean fever, the cryopyrin-associated periodic syndromes and PAPA (pyo-
genic arthritis, pyoderma gangrenosum and acne), which are all IL-1β-mediated diseases [12].
Secondly, this is the first study to directly assess the presence of cytokines in HS pus. Our find-
ings of high cytokine concentrations at the inflammatory site are in agreement with those of
Fig 6. Changes of cytokine production and of C Reactive Protein with the clinical course of HS. PBMCs were isolated and serum was sampled from
patients with Hurley III disease at baseline and after 8 weeks of treatment with etanercept. Patients are divided into those experiencing worsening of
symptoms (n = 6) or clinical improvement (n = 7) at the end of treatment. No change was defined when disease flare-ups persisted with heavy purulence.
Improvement was defined as decrease of Sartorius score more than 30% from the baseline. PBMCs were stimulated with LPS of Escherichia coliO55:B5;
with heat-killed Candida albicans (HKCA); and with heat-Staphylococcus aureus (HKSA) for the production of (A) tumour necrosis factor-alpha (TNFα), (B)
interleukin (IL)-1β, (C) IL-17 and (D) C Reactive Protein (CRP). P values refer to comparisons of change of cytokine production from the baseline between
improved and worsened cases by the Mann-Whitney U test.
doi:10.1371/journal.pone.0130522.g006
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van der Zee et al [13] who cultured biopsies of lesional skin in HS and measured their ex-vivo
cytokine production. They found increased immune reactivity for TNFα, IL-β and IL-10 in cul-
tures of the dermis and epidermis of 20 patients. However, they did not try to classify patients
according to the cytokine profile in the lesions. Thirdly, the finding that patients show different
profiles of cytokines in pus does not come as a complete surprise: Endres et al, many years ago,
could demonstrate that healthy volunteers differ with regard to the most prominent cytokine
response of their PBMCs in vitro, pointing to personalized cytokine profiles [14].
An important question is whether we may be able to predict the response to treatment with
cytokine inhibitors based on the profile in the pus. In other words, would a patient who does
not exhibit a high concentration of TNFα in the pus fail to respond to anti-TNF treatment? It
is not possible to make such a statement yet, given the relatively low number of observations.
Reported clinical efficacy of treatment with TNF antagonists is variable between studies which
have enrolled small number of patients [4, 15–20]. In the first large trial of weekly treatment
with the monoclonal antibody adalimumab, considerable efficacy was shown. Although the
primary study endpoint based on changes of the physicians’ global assessment score showed
17.9% treatment benefit compared to 3.9% of the placebo group [5], patients treated with adali-
mumab experienced considerable improvement in all secondary study outcomes i.e. reduction
of the total number of inflammatory nodules and decreases of the DLQI and of the modified
Sartorius scores. This implies that not all patients respond to anti TNF treatment and other
modes of treatment have to be explored. To that end we recently completed a pilot randomized
controlled study on anakinra in patients with HS [21]
In all cases, it would be a great benefit if clinicians would be able to predict which patients
are likely to respond to which of these expensive treatment options. From the presented data
only the reversal of the suppression of production of IL-1β and IL-17 by circulating PBMCs
after stimulation with HKSA may be helpful to this end. Reversal of the inhibited production
of these two cytokines is found within the first eight weeks after start of treatment with etaner-
cept and it is a predictor of favorable clinical responses at the end of the 24-week period of
treatment. Our findings cannot be generalized since etanercept has not documented clinical
efficacy in large-scale trials. However, they are promising for the development of some bioassay
to predict favorable clinical responses in HS.
Our findings regarding the suppressed cytokine production in PBMCs from HS patients
concur with our previous findings of a decreased LPS-induced production of TNFα and of IL-6
ex vivo in HS patients [4]. Here we extend these findings, showing that it concerns a down-reg-
ulation that is not limited to LPS, but also occurs when the cells are exposed to heat-killed S.
aureus and C.albicans that bear ligands interacting with receptors other than Toll-like receptor
4. We also demonstrate that production of IL-17, a cytokine mainly produced by T helper 17
lymphocytes and chemo-attracting neutrophils [22], is down-regulated. This means that the
down-regulation of the cytokine responses is not limited to monocyte-derived cytokines. The
IL-17 production was inversely correlated with the severity of the disease.
The findings of down-regulated ex-vivo cytokine production in an inflammatory disease
like HS are reminiscent of the state of tolerance observed during acute severe infections [23]
and with exposure to bacterial endotoxin (LPS) [24]. In these conditions the circulating cyto-
kines may be found elevated in the early phase of the disease, to be followed by a preponderant
anti-inflammatory state. In a recent study by Matusiak et al [25], elevated serum concentra-
tions of TNFα have been reported in patients with HS. These high circulating levels of TNFα
may be responsible, at least in part, for the down-regulation of cytokine production by PBMCs
after ex vivo stimulation.
Several decades of research have greatly enhanced our understanding of the molecular
mechanisms of endotoxin tolerance [24]. However it is currently unclear how these relate to
Cytokines in Hidradenitis Suppurativa
PLOS ONE | DOI:10.1371/journal.pone.0130522 June 19, 2015 12 / 15
the state of tolerance described here; the exact mechanisms cannot be easily elucidated in clini-
cal material, but nevertheless further research is necessary. The tolerance in HS pertains to the
blood and is a feature of a compartmentalized cytokine response, in which the bloodstream is
protected against cytokine action, and monocytes recruited to the site of inflammation appear
to lose their tolerant state (Fig 7). If this hypothesis is correct, then improvement of skin
inflammation with anti-TNF treatment will reverse the inhibition exerted on circulating mono-
cytes towards increased cytokine production. This is in agreement with the reversal of the inhi-
bition of the production of IL-1β and IL-17 by PBMCs seen in patients experiencing clinical
benefit from anti-TNF treatment. Our data also demonstrate that tolerance is not a conse-
quence of a depletion of inflammatory monocytes from the bloodstream. In fact, a tendency
Fig 7. A proposed scheme of pathogenesis of HS. Patients with HS have monocytosis but cytokine responses of inflammatory monocytes and T17
lymphocytes are inhibited. This inhibition is mediated for T17 cells by tumour necrosis factor-alpha (TNFα). When cells migrate to tissues from the blood
vessels through the vascular endothelium, capacity for excess production of TNFα, interleukin (IL)-1β, IL-1α, IL-6 and IL-17 is restored.
doi:10.1371/journal.pone.0130522.g007
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towards monocytosis was detected. It was also shown that when the monoclonal antibody
against TNFα adalimumab was added to the in-vitro cultures, it partially restored the decreased
IL-17 production. This suggests that the tolerance, at least for IL-17 production is driven in
part by TNFα either as a soluble ligand or in its membrane-bound form.
Our study presents two major limitations. The first is the lack of measurement of cytokines
in the skin of healthy volunteers. This was not feasible because cytokine were measured in the
pus of lesions and healthy volunteers do not have visible skin breaches to allow sampling. The
second is the observational nature of the study so that findings should be interpreted with
caution.
Conclusions
The present study shows that in HS production of pro-inflammatory cytokine is compartmen-
talized; high in skin but decreased from circulating PBMCs. Reversal of the inhibited produc-
tion of IL-1β and IL-17 by circulating PBMCs within the first 8 weeks of therapy may be one
predictor of favorable response to TNF antagonists.
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